Limits...
Formulation and evaluation of once daily minocycline hydrochloride extended release matrix tablets.

Keny RV, Mankame SA, Lourenco CF - Indian J Pharm Sci (2009)

Bottom Line: The formulated tablets were also compared with a marketed product.The results of the dissolution study indicate that formulations FC-IV, FC-V and FC-VI showed maximum drug release upto 24 h, whereas the marketed product was found to extend the release only up to 14 h.Incase of formulations containing combination of hydroxypropylmethylcellulose and ethyl cellulose (FC-I to FC-IX), the release of the drug was found to be dependent on the relative proportions of hydroxypropylmethylcellulose and ethyl cellulose used in the tablet matrix.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa-403 001, India.

ABSTRACT
The present study was aimed to develop once daily extended release matrix tablets of minocycline hydrochloride, using hydroxypropylmethylcellulose either alone or in combination with ethyl cellulose as the matrix material in different proportions. The formulated tablets were also compared with a marketed product. The results of the dissolution study indicate that formulations FC-IV, FC-V and FC-VI showed maximum drug release upto 24 h, whereas the marketed product was found to extend the release only up to 14 h. Incase of formulations containing combination of hydroxypropylmethylcellulose and ethyl cellulose (FC-I to FC-IX), the release of the drug was found to be dependent on the relative proportions of hydroxypropylmethylcellulose and ethyl cellulose used in the tablet matrix. Mathematical treatment of the in vitro drug release data suggests that, all the formulations best fitted into first order release kinetics. Drug release from the matrix occurred by combination of two mechanisms, diffusion of drug from tablet matrix and erosion of tablet surface, which was reflected from Higuchi's model and Erosion plot.

No MeSH data available.


Related in: MedlinePlus

The in vitro release profiles of minocycline from FC-IV and Marketed Product.Release profiles of minocycline from formulations; FC-IV [HPMC K15M, 26.67%; EC, 13.33%] (-♦-) and Marketed Product [MP] (-▪-). Marketed product (-▪-) used was Solodyn90, Medics Pharma, USA. Each data point represents mean±SD (n = 6).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2865789&req=5

Figure 0006: The in vitro release profiles of minocycline from FC-IV and Marketed Product.Release profiles of minocycline from formulations; FC-IV [HPMC K15M, 26.67%; EC, 13.33%] (-♦-) and Marketed Product [MP] (-▪-). Marketed product (-▪-) used was Solodyn90, Medics Pharma, USA. Each data point represents mean±SD (n = 6).

Mentions: The in vitro release rate studies were carried out in USP dissolution test apparatus Type I (Labindia, Mumbai) in simulated gastric fluid (pH 1.2±0.1) from 0 to 2 h and simulated intestinal fluid (pH 7.2±0.1) from 2 to 24 h. Rotation speed of 50 rpm at temperature of 37±0.5° and dissolution medium of 900 ml was maintained throughout the experiment[8]. At predetermined time intervals, 10 ml of sample was withdrawn and replaced with the same volume pre-warmed (37±0.5°) fresh dissolution medium. The samples withdrawn were filtered through 0.45 μ membrane filters, and drug content in each sample was analyzed after suitable dilution by UV/Vis spectrophotometer at two different wavelengths, 265 nm for samples in gastric fluid and 245.4 nm for samples in intestinal fluid. The actual content in samples was read from a calibration curve prepared with standard minocycline HCl. All dissolution studies were carried out in duplicate and repeated at least thrice. The same was carried out on marketed product for comparative evaluation. The results are shown in figs. 1 to 6.


Formulation and evaluation of once daily minocycline hydrochloride extended release matrix tablets.

Keny RV, Mankame SA, Lourenco CF - Indian J Pharm Sci (2009)

The in vitro release profiles of minocycline from FC-IV and Marketed Product.Release profiles of minocycline from formulations; FC-IV [HPMC K15M, 26.67%; EC, 13.33%] (-♦-) and Marketed Product [MP] (-▪-). Marketed product (-▪-) used was Solodyn90, Medics Pharma, USA. Each data point represents mean±SD (n = 6).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2865789&req=5

Figure 0006: The in vitro release profiles of minocycline from FC-IV and Marketed Product.Release profiles of minocycline from formulations; FC-IV [HPMC K15M, 26.67%; EC, 13.33%] (-♦-) and Marketed Product [MP] (-▪-). Marketed product (-▪-) used was Solodyn90, Medics Pharma, USA. Each data point represents mean±SD (n = 6).
Mentions: The in vitro release rate studies were carried out in USP dissolution test apparatus Type I (Labindia, Mumbai) in simulated gastric fluid (pH 1.2±0.1) from 0 to 2 h and simulated intestinal fluid (pH 7.2±0.1) from 2 to 24 h. Rotation speed of 50 rpm at temperature of 37±0.5° and dissolution medium of 900 ml was maintained throughout the experiment[8]. At predetermined time intervals, 10 ml of sample was withdrawn and replaced with the same volume pre-warmed (37±0.5°) fresh dissolution medium. The samples withdrawn were filtered through 0.45 μ membrane filters, and drug content in each sample was analyzed after suitable dilution by UV/Vis spectrophotometer at two different wavelengths, 265 nm for samples in gastric fluid and 245.4 nm for samples in intestinal fluid. The actual content in samples was read from a calibration curve prepared with standard minocycline HCl. All dissolution studies were carried out in duplicate and repeated at least thrice. The same was carried out on marketed product for comparative evaluation. The results are shown in figs. 1 to 6.

Bottom Line: The formulated tablets were also compared with a marketed product.The results of the dissolution study indicate that formulations FC-IV, FC-V and FC-VI showed maximum drug release upto 24 h, whereas the marketed product was found to extend the release only up to 14 h.Incase of formulations containing combination of hydroxypropylmethylcellulose and ethyl cellulose (FC-I to FC-IX), the release of the drug was found to be dependent on the relative proportions of hydroxypropylmethylcellulose and ethyl cellulose used in the tablet matrix.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Goa College of Pharmacy, Panaji, Goa-403 001, India.

ABSTRACT
The present study was aimed to develop once daily extended release matrix tablets of minocycline hydrochloride, using hydroxypropylmethylcellulose either alone or in combination with ethyl cellulose as the matrix material in different proportions. The formulated tablets were also compared with a marketed product. The results of the dissolution study indicate that formulations FC-IV, FC-V and FC-VI showed maximum drug release upto 24 h, whereas the marketed product was found to extend the release only up to 14 h. Incase of formulations containing combination of hydroxypropylmethylcellulose and ethyl cellulose (FC-I to FC-IX), the release of the drug was found to be dependent on the relative proportions of hydroxypropylmethylcellulose and ethyl cellulose used in the tablet matrix. Mathematical treatment of the in vitro drug release data suggests that, all the formulations best fitted into first order release kinetics. Drug release from the matrix occurred by combination of two mechanisms, diffusion of drug from tablet matrix and erosion of tablet surface, which was reflected from Higuchi's model and Erosion plot.

No MeSH data available.


Related in: MedlinePlus